Overview

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Status:
Completed

Trial end date:
2007-11-01

Target enrollment:
0

Participant gender:
All

Summary

This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Docetaxel
Sunitinib

Criteria

Inclusion Criteria:

Advanced solid tumor malignancy ECOG 0 or 1

Exclusion Criteria:

Prior treatment with with high-dose chemotherapy requiring stem cell rescue Prior
irradiation to ≥25% of the bone marrow (e.g. whole pelvis=25%) Patients with centrally
located lung lesions unless recently treated with radiotherapy